Background: Hepatitis B virus (HBV) is the leading cause of hepatocellular carci-
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with nearly 600 000 deaths in 2008, 1 and hepatitis B virus (HBV) infection is the most common cause of HCC. 2 Up to 20%-40% of patients with HBV infection may develop HCC in the absence of clinically apparent cirrhosis. 3, 4 The advent of highly potent anti-viral therapy has offered the possibility of greatly decreasing the incidence of liver-related complications, including cirrhosis and HCC, in patients with chronic hepatitis B (CHB). 5, 6 While anti-viral medications are known to reduce the risk of HCC in patients with CHB, 7 it is less well understood how they influence the overall survival of patients with established HCC, with most data only focusing on patients undergoing curative therapy for HCC. 8 A 2013 randomised controlled trial comparing nucleot(s)ide analogues to placebo in patients with HBV-related HCC treated with partial hepatectomy found that anti-viral therapy decreased the risk of HCC recurrence, HCC-related mortality and overall mortality. 9 These findings are supported by an earlier meta-analysis of 9 cohorts and a national database study showing that HCC patients receiving curative therapy for HCC and treated with anti-viral agents had decreased overall mortality and recurrence rate. 10, 11 Likewise, anti-viral therapy after radiofrequency ablation is associated with decreased HCC recurrence. 12 The data on anti-viral therapy in patients treated with palliative therapy, including transarterial chemoembolisation (TACE) and sorafenib are more limited, but in the case of TACE, a randomised controlled trial demonstrated that anti-viral therapy increases survival. [13] [14] [15] Currently, the presence of HCC is not considered an indication for anti-viral medications in international guidelines for the management of CHB. [16] [17] [18] In addition, lifelong anti-viral medications may not be reimbursed by third-party payers in certain areas such as Taiwan if patients have HCC but no cirrhosis. 19 Thus, the question of how much viral suppression can reduce mortality among HBV-related HCC patients can have important policy implications. Related to this issue is the "cascade of care" for patients with CHB, which describes the reasons for which rates of treatment for CHB are suboptimal. 20 Many patients with CHB have not even been diagnosed, and among those who are diagnosed many have not established care with the medical system. 21 Even among those with access to appropriate medical care, treatment rates of CHB are suboptimal for numerous reasons including patient loss to follow-up, financial difficulties and misconceptions about indications for anti-viral therapy. 22 A greater understanding of the use of anti-viral therapy in HBV-related HCC may provide further insight into how CHB patients interact with the healthcare system.
The goal of this study was to examine the effect of anti-viral therapy on overall survival of patients with HBV-related HCC, taking into account the presence or absence of cirrhosis in a real-world cohort of East and West patients.
| PATIENTS AND METHODS

| Study design and patient population
We performed an international multicentre cohort study of HBV- 3 | RESULTS
| Baseline clinical/tumour characteristics
The overall cohort consisted of 2518 patients, of whom 73% had cirrhosis, 81% were male, and 98% were Asian. Baseline clinical and laboratory characteristics of the patients in this cohort by anti-viral therapy status are shown in Table 1 . Among the patients with cirrhosis, 30% had had a history of hepatic decompensation with variceal bleeding, hepatic encephalopathy, or ascites, and 38% had
Child-Pugh-Turcotte (CPT) class B or C disease.
In total, 49% of patients had ever received anti-viral therapy at any time ( Figure 1 ). However, only 17% were on treatment at time of HCC diagnosis ( Figure 1 ). Proportion of patients receiving anti-viral therapy before their diagnosis of HCC did not differ between those with or without cirrhosis (17.9% vs 15.3%; P = 0.12; Figure S1A ). Of the patients who were not on therapy at time of HCC diagnosis, 37% were later started on anti-viral therapy ( Figure 1 ).
Patients with cirrhosis were more likely to receive anti-viral therapy after HCC diagnosis and more likely to receive anti-viral therapy at any time than those without cirrhosis (49.9% vs 43.1%; P < 0.001; Figure S1A ). Of note, anti-viral therapy is reimbursed in Korea for patients with detectable HBV DNA and HCC, 27 but HBV DNA was detected in 68% of patients who never received anti-viral therapy after HCC diagnosis.
Though rates of anti-viral therapy were well below 50% at time of HCC diagnosis at all centres, it was higher at the US centres than the Taiwan or Korea centres (40% vs 12% vs 10%; P < 0.001 for three-way comparison; Figure S1B ). After HCC diagnosis, 68% of the US and 61% of the Korea centre patients were on anti-viral therapy, compared to only 31% in the Taiwan centre ( Figure S1B ; P < 0.001 for three-way comparison Regarding HCC by cirrhosis status, patients with cirrhosis had smaller maximum tumour size than those without cirrhosis (5.2 vs 5.8 cm; P = 0.004) but more often had multifocal tumours (55% vs 42%; P < 0.001). Compared to patients without cirrhosis, HCC patients with cirrhosis also had a greater prevalence of vascular invasion and extrahepatic metastasis, as well as a higher BCLC stage (P < 0.001 for all comparisons). P < 0.001), though they were more likely to undergo LT (4.4% vs 1.0%; P < 0.001). While patients with cirrhosis more often received liver-directed therapy (65.5% vs 53.5%; P < 0.001), this difference was largely driven by transarterial chemoembolisation rather than curative ablations.
| Cancer treatment
When comparing cancer-directed treatment modalities based on anti-viral therapy status (Table S3) , patients receiving anti-viral therapy were more likely to receive any treatment and most individual treatments including resection, LT, and liver-directed therapy. As with cirrhosis, the difference in liver-directed therapy was driven primarily by palliative transarterial chemoembolisation and external radiation therapy. person-years in the study population. Overall, patients with cirrhosis had increased mortality rate compared to those without cirrhosis (P < 0.001). As expected, mortality was higher with higher CPT class, BCLC stage and use of curative therapies (P < 0.05 for all). Figure 4 shows overall survival based on anti-viral therapy status.
| Mortality rates and overall survival
Survival was significantly higher in patients receiving anti-viral therapy ( Figure 4A ), and notably both among those with cirrhosis (42% vs 25%; P < 0.001; Figure 4B ) and those without cirrhosis (58% vs 36%; P < 0.001; Figure 4C ). Subgroup analysis of 5-year survival based on anti-viral treatment status is shown in Table 3 (Table S4) . Patients receiving therapy before HCC diagnosis were older and had smaller maximum tumour size and more frequently had multifocal disease, vascular invasion, and extrahepatic metastases, as well as more advanced BCLC stage (Table S4 ). On analysis unadjusted for lead time, anti-viral therapy before HCC diagnosis was associated with decreased mortality vs anti-viral therapy only after HCC diagnosis (14.46 vs 19.85 deaths per 100 person-years, P = 0.0008, Figure S2A and Table S5 ). This We also compared patients receiving anti-viral therapy only after HCC diagnosis with those not receiving anti-viral therapy at all.
Here, there was no significant difference in maximum tumour size, proportion of multifocal tumours, or vascular invasion (Table S6) .
However, patients not receiving anti-viral therapy had greater proportion of extrahepatic metastasis and higher BCLC stage (42.2 vs 32.7%; P < 0.05 for both comparisons; 26 Ministry of Health and Welfare for the Republic of Korea (purple) 27 and National Health Insurance Administration for Taiwan (green) 28 (P < 0.001) but were no different in patients receiving anti-viral therapy after HCC diagnosis (P = 0.58). Table 4 ). In this model, the Taiwan centre was no longer independently associated with increased mortality. On subanalysis of the patients for whom screening information was available, both screening and anti-viral therapy were associated with increased survival in a multivariate analysis model (Table S7 ).
| Predictors of survival
| DISCUSSION
In this study, we characterised a cohort of patients with HBV-related HCC stratified by anti-viral therapy utilisation and cirrhosis status.
We found that the use of anti-viral medications at any time in HBVrelated HCC patients was associated with a 20%-40% reduction in overall mortality of these patients, a sizable effect especially when compared to the modest survival benefits seen with many standard therapies for HCC such as palliative liver-directed therapy and sorafenib. 31, 32 The benefit of anti-viral therapy holds across a range of different cancer stages including BCLC stage C/D and treatment types and even in patients receiving supportive care only. In addition, while there were significant differences in the rates of anti-viral utilisations and overall mortality among US vs Taiwan vs Korea centres, there was no difference in overall survival based on country of study sites in this multicentre international study after adjustment was made for anti-viral therapy use.
There is extensive evidence that anti-viral therapy in patients with CHB decreases risk of liver-related complications including liver decompensation and HCC development. 6, 33, 34 (Table 4) .
Disappointingly, in this multinational cohort, there was a strikingly low rate of anti-viral therapy. In particular, there was a much lower rate of anti-viral use in the Asian sites compared to the US 22 Rather, the most commonly cited reasons were the desire for further follow-up by patients and/or physicians and the perception that the patients' serum alanine aminotransferase levels
were not elevated even though they met guideline criteria. 22 Since CHB is a largely asymptomatic disease until onset of advanced HCC or end-stage liver disease, appropriate management often requires both patients and care providers to be better informed of the natural history of the disease and the need for regular monitoring and preventive therapy.
HBV-related HCC can occur in the absence of liver cirrhosis.
According to prior studies, no overt cirrhosis is seen in 20%-40% of patients with HCC in primarily Asian cohorts [37] [38] [39] [40] and approximately 10% in non-Asian cohorts. 41, 42 In this study, we found that 27% of One limitation of this study was that the vast majority of patients were of Asian ethnicity. Whether the findings can be applied to patients of other ethnicities requires further evaluation.
Because of lack of longitudinal HBV DNA data, our data likely underestimate the proportion of patients for whom therapy was ever indicated, since patients may have had higher HBV DNA concentration at an earlier date, which may argue against our claim that guidelines are inadequate for identifying high-risk patients. Finally, this study was retrospective in design, so we were not able to ascertain the reasons for lack of anti-viral therapy. A strength of this study was that it included a large number of HCC patients with HBV infection in Asian populations seen at both American as well as Asian centres. Further, all of the chart review procedures were standardised at each study site using the same case report form with similar definitions for the major outcome and predictor variables such as anti-viral therapy, liver cirrhosis and HCC.
In summary, we report here the largest cohort of diverse HBVrelated HCC patients from several medical centres from 3 countries.
We found that anti-viral therapy at any time was significantly associated with 20%-40% lower mortality and this beneficial effect was independent of age, cirrhosis status, severity of cirrhosis, cancer stage and cancer treatment. Unfortunately, this study also found an 
